Freeline Therapeutics Holdings announced that it received approval from the Nasdaq Stock Market to transfer the listing of its American Depositary Shares representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will be effective at the opening of business on November 30.The Company will continue to trade under the symbol "FRLN."
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FRLN:
- Freeline Receives Approval to Transfer to Nasdaq Capital Market
- Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease